Medication described in the protocol · Placebo comparator
Compensation
Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Study clarity
Things to check before joining
Study start dateStarted: September 13, 2024
Recruitment status
Terminated
Enrollment listed in the registry
26
Sponsor
Ironshore Pharmaceuticals and Development, Inc
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 4 Years to 5 Years
Official registry ID
NCT06431256
Official title
Show the full official title
Phase 3, Multicenter, 3-Week Fixed-dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy, Safety and PK Study of Evening Dosed Methylphenidate Hydrochloride ER Capsules (HLD200) in Children Aged 4-5 Years With ADHD
Need help understanding this study?
Leave your email and we’ll get in touch to discuss your questions and possible next steps.
Recruitment & locations
Terminated
Dothan · Anaheim · Jacksonville
10 more locations
Miami Springs
Orlando
Decatur
New Orleans
Saint Charles
Lincoln
Las Vegas
Cincinnati
Summerville
Memphis
A listed location does not confirm current availability.
FAQ
Questions about this study
Who is behind this study?
The study sponsor is Ironshore Pharmaceuticals and Development, Inc.
Does this study involve medication?
Yes. The study involves medication, including HLD200 methylphenidate hydrochloride capsules and Placebo HLD200 capsules.
Who can participate?
Listed age limits: 4 years to 5 years.
Is this study still recruiting?
The registry lists this study as terminated.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.